Restless legs syndrome (RLS) is one of the commonest movement disorders affecting sleep and also daytime functioning. The prevalence may be 8%-10% of the white Caucasian population. The diagnosis is simple and is based on a well-validated clinical questionnaire, yet misdiagnosis is common and the condition remains underdiagnosed and consequently inappropriately treated, often causing great distress to the sufferers. In spite of robust evidence for effective treatment of RLS, patients may often be told to "put up with the symptoms" and suffer the consequence of years of poor sleep which may lead to major lifestyle changes. This review addresses the diagnostic issues, the differential diagnosis, and the evidence base for treatment of the common condition.
Introduction
Restless legs syndrome (RLS), also known as Ekbom's syndrome, is a common movement disorder with sensorimotor symptoms occurring during sleep and quiet wakefulness (Ekbom 1945) . Yoakum has described RLS as the "the most common disorder you've never heard of " and this may be an appropriate description of RLS (Yoakum 1994) . The term restless legs syndrome was fi rst introduced in 1945 by Karl-Axel Ekbom, a Swedish neurologist and surgeon, who described and systematically characterized the condition (Ekbom 1945) . RLS can present in primary care and secondary care, across a range of specialities, and in the UK, the condition remains under-recognized and is often regarded as a neurosis in spite of evidence that RLS adversely affects quality of life (Chaudhuri et al 2001 Kirsch 2002; Chaudhuri et al 2003; Abetz et al 2004) . Although RLS is effectively treatable, and there is a growing evidence base for drug treatment of RLS, the condition is generally poorly treated and investigated and often prescribed inappropriate drugs.
Patients' descriptions of RLS are wide and varied, including "Elvis legs" and an "electric current" running through their legs (Allen and Earley 2001; Allen et al 2003) . With such a broad, unusual spectrum of reported sensations, RLS is frequently misunderstood and misdiagnosed, and even classifi ed as a psychogenic disorder (Allen and Early 2001; Chaudhuri 2003) . Ekbom (1945) distinguished between the sensory form of RLS (asthenia crurum paraesthetica) and the painful variant of RLS (asthenia crurum dolorosa). However, the earliest description of restless legs associated with sleep disabilities came from Sir Thomas Willis, an English physician and Sedleian professor of natural philosophy in Oxford in 1672 who alluded to RLS in a chapter titled "Instructions for curing the watching-evil" written in Latin (Willis 1672). More recently, abnormal involuntary movements during sleep such as nocturnal myoclonus (subsequently termed periodic limb movements during sleep [PLMS] ) have been reported to have a strong association with RLS (Symonds 1953; Lugaresi et al 1965) . The diagnosis of RLS had been diffi cult owing to lack of validated diagnostic criteria till 1995. The International Restless Legs Study Group defi ned and validated such criteria in 1995 (Walters 1995) . Revised criteria for the diagnosis of RLS were formulated from a consensus conference held at the National Institutes of Health on May 1-3, 2002 in Bethesda, MA, USA (Allen et al 2003) .
Historical aspects

Diagnosis and differential diagnosis
Four essential criteria are all necessary for diagnosis ( Table 1) . The supportive and associated features help in uncertain cases.
RLS needs to be differentiated from nocturnal leg cramps and positional discomfort and akathisia (Table 2) . Other differential diagnoses are noted in Table 3 (Mrowka et al 2004; Tse et al 2004) . It is clear from the above criteria that any condition that causes legs to be restless or fi dgety is not necessarily due to RLS.
Associations
Increasing age and female sex are risk factors for the development of RLS. The three common associations of RLS are iron defi ciency anaemia, renal failure-uraemia, and pregnancy (Ondo 2002; Chaudhuri 2003; Jobges et al 2004) . Association with Parkinson's disease (PD) remains Reports of RLS in patients with large fi bre and small fi bre neuropathy are variable and range from 5% to 8.8%, rates not higher than controls (Rutkove et al 1996; Ondo 2002 ; Table 1 The diagnostic criteria for RLS (Walters et al 1995) Table 2 The most common differential diagnoses of RLS (Mrowka et al 2004; Tse et al 2004) Table 3 The differences between akathisia, cramps, positional discomfort, and RLS (Mrowka et al 2004) Restless legs syndrome and management Chaudhuri 2003; Jobges et al 2004; Tse et al 2004) . During pregnancy, RLS has been reported in 11%-27% of women usually during the third trimester (Goodman et al 1988; Ondo 2002; Chaudhuri 2003) . Other secondary causes of RLS are listed in Figure 1 . PLMS were fi rst reported by Lugaresi et al (1965) and polysomnographic studies have recorded PLMS (more than fi ve per hour) in up to 87.8% of RLS patients (Lugaresi et al 1965; Montplaisir et al 1997; Garcia-Borreguero et al 2003) . Prevalence estimates of PLMS are variable and range from 6% in the general population to 58% in a subpopulation of subjects over 60 years old (Lugaresi et al 1965; Rothdach et al 2000; Garcia-Borreguero et al 2003 (Henning et al 1999; Chaudhuri 2003) . Treatment should begin by examining the patient's lifestyle and looking for opportunities to initiate lifestyle changes, especially with regard to substances known to exacerbate symptoms (Table 4) (Henning et al 1999; Chaudhuri 2003; Chaudhuri et al 2004; DeKokker et al 2005) .
In many cases not severe enough to merit pharmacological treatment, self-help measures may enable a patient to cope with symptoms of RLS. These so called "self-directed
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folate, and Mg activities" are aimed to distract the mind from the symptoms of RLS and may include:
• Asking the patient to read an interesting book during the onset of symptoms • Using a hot or cold massage • Stretching • Rubbing/massaging legs • Brief spells of exercise Sleep hygiene is often used for management of sleep disorders and can be adapted for RLS (Table 5) . It is important to ensure that patients have not been given drugs that worsen RLS (Table 6) .
Support groups such as the Ekbom Support Group, RLS: UK in the UK and websites are available to assist the patients with this distressing condition and to provide useful information and services (Chaudhuri 2003) .
Those with chronic severe symptoms or regular recurrent symptoms (Ͼ2 attacks per week) should be treated symptomatically. Primary and secondary RLS need to be differentiated and treated accordingly. The commonest secondary causes of RLS include iron defi ciency anemia, and all RLS patients must have serum ferritin levels checked (some believe transferrin receptor assays are better). Those with low normal or low ferritin levels (Ͻ45 μg/dL depending on local laboratory values) should receive oral iron supplementation for a trial period. However in many RLS patients, oral iron supplements may not be as effi cacious as previously thought. As a result, various studies have been conducted to compare oral with intravenous iron supplementation, but suffi cient data are still lacking (O'Keefe et al 1994; Henning et al 1999; Davis et al 2000; Chaudhuri 2003 ). Blood transfusions may also be considered an option for treatment in severely anemic patients with RLS.
Pharmacological treatment
Despite the fact that RLS is a treatable condition, which generally responds well to various medications, the treatment options are limited by the fact that at present none of the treatment options are licensed in the UK. It is envisaged that the situation will soon change and at least two or three products are likely to gain license for use in RLS soon. An established body of evidence is now gathered from doubleblind, placebo-controlled trials providing level 1 evidence that dopamine agonists (DAs) are effective for treatment of RLS and currently should be considered the drug of fi rst choice in most patients (Chaudhuri 2003; DeKokker et al 2005) . Before DAs were available, levodopa was considered effective for RLS, although high rates of augmentation and rebound-related complications have limited the role of levodopa in the treatment of RLS (Allen and Earley 1996; Chaudhuri 2003; DeKokker et al 2005) . Trials are being considered to look at the role of enhanced formulations of levodopa (combined with entacapone) in the treatment of variants of RLS. Tables 7 and 8 list dopaminergic and nondopaminergic (usually used as second-line treatment) treatment options available for RLS.
Dopaminergic drugs Dopamine agonists (DAs)
These are generally considered the fi rst-line pharmacological agents for both RLS and PLM, and have been proven to be very effective in relieving both (a) symptoms experienced Restless legs syndrome and management in the awake state, including the subjective feelings of discomfort and other associated movement abnormalities, and (b) problems relating to sleep and nocturnal arousals (Earley et al 1998; Chaudhuri 2003; Tse et al 2004) . Virtually all the DAs are effective to some degree. In cases where a defi nitive diagnosis of RLS has been made, a dramatic response with the use of night-time DAs is expected and some recommend use of this strategy as a challenge test for RLS (Earley et al 1998) . As a general guideline most DAs should be started well below the recommended dosage used for PD and gradually titrated upwards, in line with the clinical response. Side-effects include nausea, nasal stuffi ness, and hypotension and we routinely use domperidone prophylaxis for 2 weeks for preventing nausea. Nasal stuffi ness or postural hypotension is rarely clinically serious. Newer DAs such as cabergoline (1-4 mg nocte), pramipexole (0.5-1.5 mg nocte or in divided doses), ropinirole (0.25-4 mg nocte), rotigotine transdermal patches (4.5 mg nocte), and apomorphine (nocturnal subcutaneous infusion 18-48 mg over 12 hours) have also all recently been shown to have benefi cial effects on symptoms of RLS, PLM, and overall quality of nocturnal sleep (Reuter et al 1999; Montplaisir et al 2000; Stiasny et al 2002; Partinen et al 2004; StiasnyKolster, Benes, et al 2004; Stiasny-Kolster, Kohnen, et al 2004; Trenkwalder, Garcia-Borreguero, et al 2004; Walters et al 2004) . Several of these trials (pergolide, cabergoline, ropinirole, rotigotine, pramipexole) have all used randomized, double-blind, placebo-controlled design. Some key DAs are discussed below. Bromocriptine and pergolide Although bromocriptine (5-20 mg) was one of the fi rst DAs described in the treatment of RLS, to date pergolide has been most frequently studied (Earley et al 1998; Stiasny et al 2001) . Stiasny et al (2001) demonstrated lasting relief from symptoms throughout the night where pergolide (0.10-0.75 mg) was administered as a single evening dose or as two divided doses (0.05 mg twice daily) in two open-label trials. These fi ndings were also confi rmed in a similar trial comparing the effi cacy of pergolide (0.125-0.25 mg) with that of levodopa (250-500 mg) and also in a recently published double-blind, placebo-controlled trial (Trenkwalder, Hundemer, et al 2004; DeKokker et al 2005) . In comparison with levodopa, pergolide caused a statistically signifi cant improvement in both PLMS and RLS, while bromocriptine, in a comparative analysis with levodopa, demonstrated similar therapeutic effects in terms of relieving RLS symptoms; however, levodopa did demonstrate better tolerability (DeKokker et al 2005) . Ropinirole The recently published TREAT-RLS study is the largest trial reported so far, including 284 patients from 10 European countries, investigating the effi cacy of ropinirole in a 12-week, randomized, double-blind, placebo-controlled design followed by a 12-month open-label extension (Trenkwalder, Garcia-Borreguero, et al 2004) . At 12 weeks, ropinirole at a mean dose of 1.9 mg/day signifi cantly improved RLS severity scale scores compared with placebo (p = 0.0036). A high placebo response rate was a problem in this trial, but the improvement in clinical global impression, measures of health-related quality of life, and sleep were signifi cantly in favor of ropinirole treatment at 12 weeks. The results of the TREAT-RLS 2 study involving a total of 267 patients receiving a 0.25-4 mg evening dose of ropinirole have been published recently and have confi rmed the superiority of ropinirole over placebo in the treatment of RLS (Walters et al 2004) .
Pramipexole In a recent placebo-controlled, crossover, polysomnographic study involving 109 patients, pramipexole given at dose range of 0.125-0.75 mg/day nocte (of the salt preparation) markedly reduced restlessness and PLM during the day and night; however, its effects on sleep architecture were similar to those recorded with patients using the placebo (Montplaisir et al 1999; Partinen et al 2004) . A large multicenter European study has recently reported the effi cacy of pramipexole in the treatment of RLS (Oertel and Stiasny-Kolster 2005) . Few suffi ciently long-term follow-up studies have reported on the continued effi cacy of DA treatment. One study (Montplaisir et al 2000) reported continued effi cacy of pramipexole (0.25-0.75 mg evening dose per day) during follow-up for about 8 months, while Stiasny-Kolster, Benes, et al (2004) have reported continuing effi cacy of cabergoline at 1 year follow-up. Recent reports suggest that depression and low mood may be a problem in RLS and the proposed psychotropic action of pramipexole may be particularly useful in this regard (Corrigan et al 2000; Goldberg et al 2004) . Cabergoline Cabergoline, an ergot DA, has the longest half-life (65 hours) of all the DAs and therefore has the added advantage of being active for up to 24 hours. Work from our group and others has demonstrated the effi cacy of cabergoline in PD patients with RLS, and it has recently been proven to be well tolerated in both young and elderly patients, with acceptable side-effect profi les (Appiah-Kubi et al 2002 , 2003 . Studies suggest that cabergoline is well tolerated in patients with severe RLS who have failed other therapies and also those experiencing augmentation (Appiah-Kubi et al 2002) . More recently, a double-blind, placebo-controlled trial in 85 patients randomized to placebo and 0.5, 1, and 2 mg of cabergoline reported marked improvement of RLS severity at bedtime and during the day and satisfaction with sleep compared with placebo with all doses of cabergoline throughout a 1-year follow-up period (Stiasny-Kolster, Benes, et al 2004) .
Rotigotine and apomorphine Rotigotine is a nonergot agonist used as a cutaneous patch. In a randomized, doubleblind, placebo-controlled trial involving 63 patients with RLS, rotigotine signifi cantly reduced RLS severity scores compared with placebo at 4.5 mg daily dose (StiasnyKolster et al 2002; Stiasny-Kolster, Kohnen, et al 2004) .
Further trials using rotigotine transdermal delivery system for RLS are underway. Apomorphine, a subcutaneously administered nonergot DA, has also been shown to be effective for symptoms of RLS used as an overnight infusion in severe cases (Reuter et al 1999) . Sumanirole, a dual-acting DA, has been evaluated in a double-blind manner for the treatment of RLS but has been withdrawn from clinical development.
Other dopaminergic drugs reported to be of benefi t in RLS include orphenadrine, piribedil, dihydroergocriptine, and amantadine (Henning et al 1999; Stiasny et al 2001; Chaudhuri 2003; DeKokker et al 2005) . In future, decision of which DA to use will depend on licensing, cost of the DA, and the clinician's familiarity with the drug and side-effect profi le, particularly the relative merits of using a nonergot versus an ergot agonist. Ergot agonists have been linked to a small risk of cardio-pleuro-pulmonary fi brosis, while nonergot agonists seem to have a slightly increased risk of inducing sudden sleep onset in susceptible patients. However, these observations were found only in PD patients and their relevance to RLS patients is unclear. Levodopa Eight small-scale, double-blind and seven openlabel studies have shown that levodopa in conjunction with a peripheral decarboxylase inhibitor (100 mg levodopa with 25 mg carbidopa or benserazide) is consistently effective for treatment of RLS symptoms (Ondo 2002; Allen et al 2003; Jobges et al 2004) . However, the benefi ts of levodopa treatment are complicated by the emergence of treatment-related side effects such as rebound and augmentation. a) Rebound (Atlas Task Force 1993; Chaudhuri 2004) represents re-emergence of RLS symptoms in the later part of the night or shortly after waking in the morning, and often necessitates the use of a second dose during the night, taken later at night, or alternatively the use of a slow-release formula. This phenomenon may occur due to the short half-life of levodopa. b) Augmentation Early 1996, 2001; Chaudhuri 2004 ) is a paradoxical effect associated with levodopa
Restless legs syndrome and management (and DAs to a lesser extent), involving the loss of effi cacy, the earlier onset of RLS symptoms before the scheduled dosage, a shorter latency to the onset of the RLS symptoms while at rest, involvement of other body parts (ie, arms), or an actual worsening in reported RLS symptoms. This phenomenon has been demonstrated in patients on long-term therapy as well as in some patients shortly after starting levodopa therapy, and the augmentation rate following chronic levodopa use has been reported to be as high as 85% (Chaudhuri 2004; DeKokker et al 2005) . DAs also appear to be superior to levodopa based on a handful of comparative studies. One study reported that pergolide was superior to levodopa in suppressing PLM (79% vs 45%), while another study reported a greater improvement in RLS severity scale following ropinirole (1.45 mg/day, 73.5%) compared with levodopa (190 mg/day, 33.5%) in hemodialysis patients with RLS (Allen et al 2003; Jobges et al 2004) .
Controlled-release levodopa prolongs the therapeutic effect into the second half of the night and may, therefore, be suitable for reducing rebound. The role of standard levodopa used with an additional catechol-O-methyltransferase (COMT) inhibitor such as entacapone, or Stalevo (a combined preparation of levodopa with entacapone), is being investigated and this strategy may prove particularly beneficial for patients who need to take treatment in an intermittent basis, such as during long fl ights. Augmentation with DAs and management Augmentation, although uncommon, has been occasionally reported with the use of other DAs. Some claim that rates can be as high as 27% with pergolide but these symptoms are often mild and helped by an afternoon dose. Augmentation has been reported in up to 7% of patients on pramipexole and our observations suggest in about 2%-3% of cases on cabergoline (Atlas Task Force 1993; O'Keefe et al 1994; Kirsch et al 2002; DeKokker et al 2005) . However, a recent trial by Stiasny-Kolster et al reports an augmentation rate of 9% at 1 year in those taking cabergoline (Stiasny-Kolster, Benes, et al 2004) . Augmentation is also rarely seen with the use of ropinirole. An additional early afternoon dose is helpful, but in some patients the dose of the agonist needs to be increased to the full dose. If this fails, a switch to an alternative agonist or a nondopaminergic agent such as gabapentin needs to be considered.
Nondopaminergic drugs
Anti-epilepetic drugs Gabapentin and carbamazepine have been most widely evaluated in open-label and double-blind studies. Recently, Garcia-Borreguero and colleagues reported the results of a double-blind, crossover, polysomnography-controlled study with gabapentin in 24 patients. Gabapentin at doses up to 1850 mg/day improved periodic limb movements, sleep architecture, and pain scores (Garcia-Borreguero et al 2003) . At 6 weeks, no augmentation was observed. In a 4-week, open, randomized trial, gabapentin was also compared with the DA ropinirole and was as effective as ropinirole in symptom reduction. A double-blind, randomized, controlled trial of carbamazepine showed effective reduction in the number of episodes of restless legs per week, but PLMS was not consistently reduced (Jobges et al 2004) . Levetiracetam and pregabaline have also been reported to be benefi cial in RLS. We feel that gabapentin seems to be benefi cial particularly in cases of RLS associated with painful sensations, and studies have reported that gabapentin may be benefi cial for RLS associated with uremia and hemodialysis (Tse et al 2004; DeKokker et al 2005) . One open trial has reported similar effi cacy of gabapentin (800 mg daily) to ropinirole (0.8 mg daily) (Happe et al, 2003) .
Opioids
In the 17th century, opiates were actually used in the treatment of conditions that closely resembled RLS. In double-blind, placebo-controlled trials, several workers have reported the benefi cial effects of drugs such as oxycodone and propoxyphone in providing symptomatic relief of both RLS and PLMS (Allen et al 1992; Walters et al 1993; Henning et al 1999) . Stronger opioids such as methadone, levorphanol, and sustained-release morphine should be reserved for the treatment of severe cases and for those not responding to dopaminergic treatment or in RLS associated with pain (asthenia crurum dolorosa) (Tse et al 2004) . More recently, Ondo (2005) has reported the sustained effi cacy and good tolerability of methadone (5-40 mg/day) in RLS patients who failed dopaminergic treatment, with a 75% reduction in symptoms and no augmentation between 4 and 44 months. ; clonazepam is the only benzodiazepine to be studied in controlled trials. Two double-blind, crossover studies involving only six patients reported contradictory results -either no or modest benefi t in leg symptoms and sleep (Tse et al 2004) . Overall, studies suggest that clonazepam can be helpful for treatment of RLS. An added benefi t, relating specifi cally to clonazepam, is that it has also been successful in the treatment of related motor sleep disorders, such as rapid eye movement (REM) behavior disorders, which may coexist in patients suffering from RLS (Chaudhuri 2003) . However, the confounding effect of benzodiazepines on sleep architecture, respiratory depression, and dependence are concerns, although in a single study conducted with patients with nocturnal respiratory disturbances, benzodiazepines were well tolerated (Stisany et al 2001; Tse et al 2004) . Additional (to levodopa or DAs) dosing of a benzodiazepine may help when insomnia is associated with RLS. The role of modern sedatives such as zolpidem, zopiclone, and zaleplon in the treatment of RLS has not been established to date.
Adrenergic drugs
Clonidine, a centrally acting alpha adrenergic blocker, suppresses noradrenergic activity and at doses of 0.15-0.9 mg/day can be effective for idiopathic and uremic RLS cases (Tse et al 2004) . One randomized, double-blind, placebo-controlled trial of clonidine at a mean dose of 0.5 mg/day showed greater subjective improvement of sensory symptoms and motor restlessness, and faster sleep onset, compared with placebo but no effect on PLM (Wagner et al 1996) . For patients, whose symptoms are most prominent in the period just before sleep onset, clonidine might be especially useful. However, use of clonidine for RLS is complicated by its adverse effect profi le, which aggravates depression and insomnia and may cause hypertensive crises with abrupt discontinuation (Tse et al 2004) . Baclofen has also been studied but was shown to increase PLMS (Tse et al 2004) .
Iron
Iron defi ciency is implicated in the causation of RLS and an open-label trial showed that oral iron (200 mg thrice daily) was benefi cial in those with low ferritin levels (Ͻ18 ng/mL) (O'Keefe et al 1994; Tse et al 2004) . However, a double-blind, placebo-controlled trial in RLS patients with normal or high ferritin levels reported no benefi t with oral iron therapy (Davis et al 2000) . In those with normal serum iron levels, intravenous iron improved symptoms in 21 out of 22 patients (Tse et al 2004) . We feel that iron administration is likely to be helpful for iron-defi cient patients with RLS, and we would use oral iron supplementation in patients with serum ferritin levels below 45-50 μg/dL. Oral treatment may take several months to be effective, but intravenous iron treatment may be poorly tolerated and is not recommended for general use (Tse et al 2004) . A double-blind trial investigating the safety and effi cacy of intravenous iron in the treatment of RLS is underway in the USA.
Other treatment issues
Therapy of RLS in children, pregnant women, and the elderly is less well understood and rather poorly documented and needs further large-scale trials. Many of the drugs are not safe to use in pregnancy.
Secondary RLS
The primary causes of secondary RLS such as iron deficiency, uremia, or neuropathy needs to be investigated and treated. Most drugs listed above work in secondary RLS and evidence suggests that gabapentin or clonidine may have a good effect in RLS related to renal failure, while opioids are useful in pain-dominant secondary RLS. RLS and PLM occur in PD , and in such situations patients may need targeted night-time treatment for RLS with long-acting dopaminergic agents such as cabergoline or pramipexole (Appiah-Kubi et al 2002). Okun et al (2005) have reported resolution of RLS symptoms in a patient with dystonia treated by deep-brain stimulation of the internal globus pallidus.
Conclusions
RLS and PLM are common problems and in most patients may not require pharmacological treatment at diagnosis, but correct diagnosis, counselling, and reassurance are essential. Sadly, often these do not occur, causing patients and caregivers great distress due to regular sleepless nights and limb discomfort. The diagnosis of RLS can be made in the clinic in a matter of minutes without any sophisticated tests. The availability of effective treatment, which may have a dramatic effect on symptoms and quality of life, means physicians must be aware of the condition so that RLS no longer remains the "commonest condition you have never heard off ".
